Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice.
To propose a standardized approach to MDS evaluation in bone marrow specimens by (1) enhancing interinstitutional and intrainstitutional collaborations and clinical decision-making among hematopathologists and clinical hematologists and (2) allowing for efficient data extraction for clinical trials, institutional databases, and registry templates. This suggested approach is summarized in a modifiable, user-friendly template for hematopathologists to reference as they examine bone marrows (in the Supplemental Digital Content).
We built upon the bone marrow template reporting guideline outlined by the College of American Pathologists Pathology and Laboratory Quality Center for Evidence-Based Guidelines and gathered expert insight from hematopathologists and hematologists-oncologists who specialize in MDS.
This proposed approach to MDS evaluation in the bone marrow standardizes reporting, which enhances communication among health care professionals and allows for efficient data extraction.
Author notes
Grant support for Santini is provided by the Associazione italiana ricerca sul Cancro (AIRC) IG26537-2021 (Investigator Research Grant). Grant support for Della Porta is provided by 5 × 1000 MYNERVA (Myeloid Neoplasms Research Venture AIRC)—project #21267 and European Union—Next Generation EU—NRRP M6C2 (Investment 2.1 Enhancement and strengthening of biomedical research in the NHS)—Project PNRR-MAD-2022-12376695. Grant support for Komrokji is provided by Bristol Myers Squibb (BMS). Zeidan is a Leukemia and Lymphoma Society Scholar in Clinical Research.
Our article is written on behalf of the International Workshop on Myelodysplastic Syndromes, an international expert panel composed of hematopathologists, hematologists, hematologist-oncologists, and clinical researchers dedicated to optimizing care for patients with myelodysplastic syndromes/neoplasms (https://iwmds.org).
Savona serves on the board/advisory committee for Bristol Myers Squibb, CTI, Forma, Geron, GSK, Karyopharm, Rigel, Ryvu, Taiho, Takeda, and Treadwell; has consultancy and equity ownership with Empath Biosciences, Karyopharm, and Ryvu; and receives research support from ALX Oncology, Astex, Incyte, and Takeda. The other authors have no relevant financial interest in the products or companies described in this article.
Zeidan and Xu contributed equally
Gisriel is currently located at the Department of Pathology and Laboratory Medicine, University of Wisconsin–Madison
Aakash is currently located at the Department of Pathology, University of Texas Medical Branch, Galveston